Suggested remit: To appraise the clinical and cost effectiveness of ibrutinib with R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone) within its marketing authorisation for untreated mantle cell lymphoma when an autologous stem cell transplant (ASCT) is suitable.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6596
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 November 2025 | Invitation to participate |
| 16 September 2025 - 14 October 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6596 |
| 16 September 2025 | In progress. Scoping commencing |
| 18 June 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual